Simlandi Kit
Product Images NDC 51759-412

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Simlandi (NDC 51759-412). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton1pk (Simlandi Carton 1pk 15)

This is a medication packaging for Simlandi containing adalimumab-ryvk in the form of an injection. It is a single-dose autoinjector for subcutaneous use. The package includes alcohol prep pads, instructions for use, a medication guide, and prescribing information. The dosage is 40 mg/0.4 mL. The product is labeled for prescription use only.*

FDA Label Image

Carton2pk (Simlandi Carton 2pk 15)

This is a description of a medication called Simlandi, containing adalimumab-ryvk in a 40 mg/0.4 mL injection form for subcutaneous use. Each carton contains 2 autoinjectors for single-dose administration along with alcohol preps, instructions for use, medication guide, and prescribing information. It is intended for subcutaneous use only and is available in Braille. The National Drug Code (NDC) for this medication is 51759-402-02.*

FDA Label Image

1 (Simlandi Injection Bla761299 1)

FDA Label Image

1 (Simlandi Injection Bla761299 10)

FDA Label Image

1 (Simlandi Injection Bla761299 11)

FDA Label Image

1 (Simlandi Injection Bla761299 12)

FDA Label Image

1 (Simlandi Injection Bla761299 13)

FDA Label Image

1 (Simlandi Injection Bla761299 14)

FDA Label Image

1 (Simlandi Injection Bla761299 15)

FDA Label Image

1 (Simlandi Injection Bla761299 16)

FDA Label Image

1 (Simlandi Injection Bla761299 17)

FDA Label Image

1 (Simlandi Injection Bla761299 18)

FDA Label Image

1 (Simlandi Injection Bla761299 19)

FDA Label Image

1 (Simlandi Injection Bla761299 2)

This is a comparison of ASAS 20 response between a placebo group with 107 participants and an adalimumab group with 208 participants over a period of 24 weeks. The graph displays the response time in weeks on the x-axis.*

FDA Label Image

1 (Simlandi Injection Bla761299 3)

FDA Label Image

1 (Simlandi Injection Bla761299 4)

FDA Label Image

1 (Simlandi Injection Bla761299 5)

FDA Label Image

1 (Simlandi Injection Bla761299 6)

FDA Label Image

1 (Simlandi Injection Bla761299 7)

FDA Label Image

1 (Simlandi Injection Bla761299 8)

FDA Label Image

1 (Simlandi Injection Bla761299 9)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.